Products - Heart failure | Topic | NICE

Showing 9 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2023
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 May 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2016
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2014
Ivabradine for treating chronic heart failure (TA267)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 November 2012